Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach

Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Jadwiga Nessler
Formato: article
Lenguaje:EN
Publicado: Termedia Publishing House 2021
Materias:
R
Acceso en línea:https://doaj.org/article/7df11093d00449928650f3e7ff95d42c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7df11093d00449928650f3e7ff95d42c
record_format dspace
spelling oai:doaj.org-article:7df11093d00449928650f3e7ff95d42c2021-12-02T19:19:13ZDapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach1734-93381897-429510.5114/aic.2021.107491https://doaj.org/article/7df11093d00449928650f3e7ff95d42c2021-07-01T00:00:00Zhttps://www.termedia.pl/Dapagliflozin-in-the-treatment-of-patients-with-heart-failure-with-reduced-left-ventricular-ejection-fraction-a-practical-approach,35,44586,1,1.htmlhttps://doaj.org/toc/1734-9338https://doaj.org/toc/1897-4295Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF) is supported by large-scale randomized clinical trials (RCTs), reflected in the ESC/HFA treatment recommendations. The use of -blockers, inhibitors of the renin-angiotensin aldosterone system (RAA), including angiotensin converting enzyme ACE/ARB inhibitors, angiotensin and neprilysin receptor blockers (ARNI) and mineralocorticoid receptor antagonists (MRA) have been a solid basis for triple HFrEF therapy over the last few years, partially altering the natural history of patients with HF. Despite this, the 5-year survival rate in HF is still lower than for some types of cancer. Therefore, the search for new drugs to improve the prognosis of this disease is still ongoing. A new group of drugs – the so-called flozins, i.e. – is a great hope for a change in the natural history of heart failure. The following article presents practical aspects of using these drugs in the treatment of patients with HFrEF, taking into account both the inclusion criteria and various clinical profiles of patients.Jadwiga NesslerTermedia Publishing Housearticleheart failure with reduced left ventricular ejection fraction (hfref) flozins – sodium-glucose cotransporter type 2 (sglt-2) inhibitors (sglt 2) dapagliflozin indications for use patients’ clinical profiles.MedicineRENAdvances in Interventional Cardiology, Vol 17, Iss 2, Pp 135-140 (2021)
institution DOAJ
collection DOAJ
language EN
topic heart failure with reduced left ventricular ejection fraction (hfref)
flozins – sodium-glucose cotransporter type 2 (sglt-2) inhibitors (sglt 2)
dapagliflozin
indications for use
patients’ clinical profiles.
Medicine
R
spellingShingle heart failure with reduced left ventricular ejection fraction (hfref)
flozins – sodium-glucose cotransporter type 2 (sglt-2) inhibitors (sglt 2)
dapagliflozin
indications for use
patients’ clinical profiles.
Medicine
R
Jadwiga Nessler
Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
description Because of its frequent occurrence, poor prognosis, low quality of life of patients accompanying the disease and high costs associated with treatment heart failure is a significant health problem in modern cardiology. The treatment of patients with heart failure and reduced ejection fraction (HFrEF) is supported by large-scale randomized clinical trials (RCTs), reflected in the ESC/HFA treatment recommendations. The use of -blockers, inhibitors of the renin-angiotensin aldosterone system (RAA), including angiotensin converting enzyme ACE/ARB inhibitors, angiotensin and neprilysin receptor blockers (ARNI) and mineralocorticoid receptor antagonists (MRA) have been a solid basis for triple HFrEF therapy over the last few years, partially altering the natural history of patients with HF. Despite this, the 5-year survival rate in HF is still lower than for some types of cancer. Therefore, the search for new drugs to improve the prognosis of this disease is still ongoing. A new group of drugs – the so-called flozins, i.e. – is a great hope for a change in the natural history of heart failure. The following article presents practical aspects of using these drugs in the treatment of patients with HFrEF, taking into account both the inclusion criteria and various clinical profiles of patients.
format article
author Jadwiga Nessler
author_facet Jadwiga Nessler
author_sort Jadwiga Nessler
title Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
title_short Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
title_full Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
title_fullStr Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
title_full_unstemmed Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
title_sort dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
publisher Termedia Publishing House
publishDate 2021
url https://doaj.org/article/7df11093d00449928650f3e7ff95d42c
work_keys_str_mv AT jadwiganessler dapagliflozininthetreatmentofpatientswithheartfailurewithreducedleftventricularejectionfractionapracticalapproach
_version_ 1718376860810739712